UA101010C2 - Производное 6,7-диалкоксихиназолина, пригодное для лечения расстройств, связанных с раком - Google Patents

Производное 6,7-диалкоксихиназолина, пригодное для лечения расстройств, связанных с раком

Info

Publication number
UA101010C2
UA101010C2 UAA201010197A UAA201010197A UA101010C2 UA 101010 C2 UA101010 C2 UA 101010C2 UA A201010197 A UAA201010197 A UA A201010197A UA A201010197 A UAA201010197 A UA A201010197A UA 101010 C2 UA101010 C2 UA 101010C2
Authority
UA
Ukraine
Prior art keywords
surprisingly
dialkoxy
treatment
related disorders
chemical entities
Prior art date
Application number
UAA201010197A
Other languages
English (en)
Ukrainian (uk)
Inventor
Прасад Раманадхам Йотхи
Кали Сатия Бхуджанга рао Адибхатла
Рао Боллепалли Нагешвара
Чоудари Наннапанени Венкаиах
Original Assignee
Натко Фарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Натко Фарма Лимитед filed Critical Натко Фарма Лимитед
Publication of UA101010C2 publication Critical patent/UA101010C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Было выявлено, что производные хиназолина, которые содержат 3-этиниланилиновую группу в положении 4 и специфически замещенные алкоксигруппы в положениях 6 и 7, имеют более мощные и специфические антипролиферативные свойства по сравнению с другими известными соединениями хиназолинового класса лекарственных средств.Также, соединения по данному изобретению неожиданно оказались намного менее токсичными, а их профиль безопасности - чрезвычайно преобладающим для терапевтического применения.Новые химические соединения, описанные в данном изобретении, обозначены общей структурой (I) и не были синтезированы ранее, а также исследованы на предмет терапевтической пригодности и профиля безопасности.Соединение (I) представляет собой NRC-2694, если она имеет структуру (А).
UAA201010197A 2008-01-18 2008-01-18 Производное 6,7-диалкоксихиназолина, пригодное для лечения расстройств, связанных с раком UA101010C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000036 WO2009090661A1 (en) 2008-01-18 2008-01-18 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders

Publications (1)

Publication Number Publication Date
UA101010C2 true UA101010C2 (ru) 2013-02-25

Family

ID=39769348

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201010197A UA101010C2 (ru) 2008-01-18 2008-01-18 Производное 6,7-диалкоксихиназолина, пригодное для лечения расстройств, связанных с раком

Country Status (27)

Country Link
US (5) US8143250B2 (ru)
EP (2) EP2229369B1 (ru)
JP (1) JP2011509995A (ru)
KR (2) KR101762306B1 (ru)
CN (1) CN101918374A (ru)
AP (1) AP2886A (ru)
AU (1) AU2008347940A1 (ru)
BR (1) BRPI0822012A2 (ru)
CA (1) CA2711737C (ru)
CY (1) CY1118193T1 (ru)
DK (2) DK3012251T3 (ru)
EA (1) EA018514B1 (ru)
ES (2) ES2642159T3 (ru)
HR (1) HRP20161522T1 (ru)
HU (1) HUE030640T2 (ru)
IL (1) IL207046A (ru)
LT (1) LT2229369T (ru)
MA (1) MA32081B1 (ru)
MX (1) MX2010007852A (ru)
NZ (1) NZ586946A (ru)
PL (1) PL2229369T3 (ru)
PT (1) PT2229369T (ru)
SG (1) SG187490A1 (ru)
SI (1) SI2229369T1 (ru)
UA (1) UA101010C2 (ru)
WO (1) WO2009090661A1 (ru)
ZA (1) ZA201005116B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2229369T (lt) * 2008-01-18 2016-09-26 Natco Pharma Limited 6,7-dialkoksi-chinazolino dariniai, tinkami panaudoti su vėžiu susijusių susirgimų gydymui
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
CN101857618B (zh) * 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
CN103874696B (zh) * 2011-10-12 2015-06-03 苏州韬略生物科技有限公司 作为激酶抑制剂的喹唑啉衍生物及其使用方法
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
EP2796451B1 (en) * 2011-12-20 2018-08-01 Wei Qian Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
ES2899145T3 (es) 2017-04-15 2022-03-10 Natco Pharma Ltd Un proceso mejorado para la preparación de diclorhidrato de N-(3-etinilfenil)-7-metoxi-6-(3-morfolinopropoxi)quinazolin-4-amina
CN111499577A (zh) * 2019-01-30 2020-08-07 华东师范大学 邻二苯基取代五元含氮芳杂环类类化合物及其应用
AU2022291015A1 (en) 2021-06-10 2023-12-21 Natco Pharma Limited Egfr inhibitor for the treatment of head and neck cancer
GB202108302D0 (en) * 2021-06-10 2021-07-28 Natco Pharma Ltd New treatment
CN115518071B (zh) * 2021-06-24 2024-03-19 中国人民解放军联勤保障部队第九〇一医院 一种化合物在制备抗食管癌的药物中的应用
WO2024121861A1 (en) * 2022-12-08 2024-06-13 Natco Pharma Limited Egfr inhibitor for the treatment of head and neck cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US690221A (en) 1901-06-20 1901-12-31 Frederik Christian Viggo Arp Stand for cycles.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE122005000053I2 (de) 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (ru) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
WO2005070909A1 (en) 2004-01-22 2005-08-04 Natco Pharma Limited An improved process for the preparation of gefitinib
WO2006090413A1 (en) 2005-02-23 2006-08-31 Natco Pharma Limited Novel crystalline form of gefitinib and a process for its preparation
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7960545B2 (en) 2005-11-23 2011-06-14 Natco Pharma Limited Process for the prepartion of erlotinib
LT2229369T (lt) * 2008-01-18 2016-09-26 Natco Pharma Limited 6,7-dialkoksi-chinazolino dariniai, tinkami panaudoti su vėžiu susijusių susirgimų gydymui

Also Published As

Publication number Publication date
MX2010007852A (es) 2010-11-30
CA2711737A1 (en) 2009-07-23
IL207046A0 (en) 2010-12-30
US8921362B2 (en) 2014-12-30
KR101640161B1 (ko) 2016-07-15
DK3012251T3 (en) 2017-10-09
ES2593321T3 (es) 2016-12-07
DK2229369T3 (en) 2016-12-12
EA018514B1 (ru) 2013-08-30
US20110034459A1 (en) 2011-02-10
IL207046A (en) 2015-09-24
CY1118193T1 (el) 2017-06-28
PL2229369T3 (pl) 2017-01-31
EP2229369B1 (en) 2016-08-17
ZA201005116B (en) 2011-03-30
AU2008347940A1 (en) 2009-07-23
EP3012251A1 (en) 2016-04-27
EA201001173A1 (ru) 2011-04-29
BRPI0822012A2 (pt) 2015-07-21
KR20100121468A (ko) 2010-11-17
SG187490A1 (en) 2013-02-28
WO2009090661A1 (en) 2009-07-23
KR101762306B1 (ko) 2017-07-27
EP3012251B1 (en) 2017-08-30
US8143250B2 (en) 2012-03-27
HRP20161522T1 (hr) 2017-02-10
KR20160086969A (ko) 2016-07-20
US20170079983A1 (en) 2017-03-23
NZ586946A (en) 2012-06-29
US20110039844A1 (en) 2011-02-17
WO2009090661A9 (en) 2010-06-17
SI2229369T1 (sl) 2016-11-30
PT2229369T (pt) 2016-11-24
AP2886A (en) 2014-05-31
EP2229369A1 (en) 2010-09-22
HUE030640T2 (en) 2017-06-28
US20150141421A1 (en) 2015-05-21
US20190201408A1 (en) 2019-07-04
MA32081B1 (fr) 2011-02-01
US9481655B2 (en) 2016-11-01
CN101918374A (zh) 2010-12-15
ES2642159T3 (es) 2017-11-15
CA2711737C (en) 2015-03-31
AP2010005357A0 (en) 2010-08-31
LT2229369T (lt) 2016-09-26
JP2011509995A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
UA101010C2 (ru) Производное 6,7-диалкоксихиназолина, пригодное для лечения расстройств, связанных с раком
WO2008024978A3 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
WO2009016410A3 (en) Chemical compounds 831
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
NZ593684A (en) Novel vanilloid receptor ligands and their use for producing medicaments
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
HK1133787A1 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
EP1885722A4 (en) QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MY155695A (en) Quinoxalinedione derivatives
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
WO2007065662A3 (en) Trisubstituted quinazolinone derivatives as vanilloid antagonists
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
MX2009010505A (es) Derivados de piridina y pirimidina como antagonistas de mglur2.
ATE530176T1 (de) Verwendung von kaffeesäure und ihren derivaten gegen krebs
ATE481972T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür